To facilitate precise therapeutic targeting, it is essential to distinguish between three distinct biological entities: the native intracellular Breakpoint Cluster Region (BCR) protein (a GTPase-activating and kinase-active signaling scaffold), the oncogenic BCR-ABL1 fusion tyrosine kinase (the driver of Chronic Myeloid Leukemia), and the immunological B-Cell Receptor (BCR) complex (a multi-subunit cell-surface signaling complex comprising CD79A, CD79B, and membrane-bound immunoglobulins). Each entity demands highly specialized reagents and validation strategies for drug discovery.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BCR, BCR-ABL1, and B-Cell Receptor complex drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| BCR (Native / Fusion Scaffold) | Recombinant BCR coiled-coil domain or full-length native protein. High purity (>95%), Sequence Verified, Theoretical MW confirmed. Ideal for oligomerization and protein-protein interaction (PPI) inhibition assays. | View BCR Products |
| BCR-ABL1 Resistance Mutants | Recombinant ABL1 kinase domain mutants (e.g., T315I, G250E, E255K) co-expressed with BCR scaffold regions. Sequence verified, high purity, endotoxin controlled. | View ABL1 Products |
| B-Cell Receptor Complex (CD79B) | CD79B Extracellular Domain (ECD) recombinant proteins (HEK293 expressed, native glycosylation) and anti-CD79B benchmark antibodies (Polatuzumab sequence). | View CD79B Products |
| B-Cell Receptor Complex (CD79A) | CD79A recombinant proteins and siRNA validation sets for surface receptor complex assembly and signaling studies. | View CD79A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Differentiating native BCR scaffold inhibition from ABL1 kinase inhibition | Domain-specific recombinant BCR proteins (coiled-coil, DH, and PH domains) strictly verified by mass spectrometry and purity chromatography (>95%). |
| Overcoming TKI resistance mutations in BCR-ABL1 fusions | Comprehensive panel of recombinant mutant proteins (including gatekeeper T315I) with precise sequence verification. |
| Targeting B-Cell Receptor complex cell-surface components | HEK293-expressed CD79A and CD79B heterodimers preserving native post-translational glycosylations. |
| Assay background noise and antibody cross-reactivity | Sequence-defined, recombinant clinical benchmark antibodies (biosimilars) and sequence-verified siRNA validation sets. |
Live BCR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (BCR-ABL & B-Cell Receptor Targets)
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The therapeutic targeting of BCR-related pathways is undergoing a major evolution. While tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein remain the gold standard for Chronic Myeloid Leukemia (CML), drug resistance mediated by kinase domain mutations (such as T315I) has shifted research towards allosteric inhibitors (targeting the ABL myristoyl pocket) and PROTAC-mediated degradation of the entire BCR-ABL1 fusion scaffold. Concurrently, in B-cell malignancies, therapeutics targeting the cell-surface B-Cell Receptor (BCR) complex have transitioned from small-molecule kinase inhibitors (BTK/PI3K inhibitors) to antibody-drug conjugates (ADCs) and bispecific antibodies directed against surface subunits like CD79B.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Allosteric Inhibitors / Degraders (PROTACs) | Novartis, Bristol Myers Squibb, Arvinas | CML, Philadelphia chromosome-positive ALL | Intact BCR-ABL1 fusion proteins and mutant panels to verify target binding and ternary complex formation. |
| Antibody-Drug Conjugates (ADCs) | Genentech/Roche | Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma | High-purity, native glycosylated CD79B ECD-Fc fusion proteins for internalization and affinity assays. |
| Bispecific Antibodies / CAR-T | Regeneron, AbbVie, various biotech players | B-cell Malignancies, Autoimmune Diseases | Stable cell lines expressing CD79A/CD79B complexes generated via Lentivirus Premade Particles. |